As Senior Vice President, Global Biologics Operations, Per leads the global biologics operations network, which includes five internal manufacturing sites across four countries, as well as the external biologics supply network. Since April 2020, Per has also served as co-lead for the COVID-19 vaccine program, AZD1222, during which he has led the rapid establishment and start-up of a complex manufacturing network of more than 20 partners across more than 15 countries.
Throughout his 24 years within AstraZeneca, Per has significant global experience across all aspects of manufacturing and supply having worked at sites in the UK, US and Sweden. Prior to assuming his current role in 2019, he successfully led Europe, Middle East and Africa (EMEA) Supply through a period of change during which the region strengthened its focus on manufacturing excellence and people development. He previously served in executive-level positions leading Global Supply Chain & Strategy, Sweden Operations and iPR Pharmaceuticals. Per holds a master’s degree in Chemical Engineering from the Royal Institute of Technology in Stockholm, Sweden.
It is very important to us at AstraZeneca that we can produce as much vaccine as possible to ensure broad, equal access as soon as possible after a potential approval. Accelerating production at this kind of scale requires partners around the world with capabilities to manufacture using our standard process to ensure consistency and quality of the vaccine. We are working tirelessly to establish mass supply globally so if our vaccine is approved by regulators, it will be ready for distribution.
Rapid establishment of global supply mechanism for COVID-19 vaccine candidate, AZD1222
Senior Vice President Global Biologics
Appointed to lead and develop the Global Biologics organization and our internal and external supply network for biologics and vaccines during a time of significant growth
Senior Vice President EMEA Supply